JP2016539929A - 免疫療法のためのポリクローナルγδＴ細胞 - Google Patents

免疫療法のためのポリクローナルγδＴ細胞 Download PDF

Info

Publication number
JP2016539929A
JP2016539929A JP2016525990A JP2016525990A JP2016539929A JP 2016539929 A JP2016539929 A JP 2016539929A JP 2016525990 A JP2016525990 A JP 2016525990A JP 2016525990 A JP2016525990 A JP 2016525990A JP 2016539929 A JP2016539929 A JP 2016539929A
Authority
JP
Japan
Prior art keywords
cells
cell
aapc
polyclonal
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016525990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539929A5 (enExample
Inventor
ローレンス ジェイ．エヌ． クーパー
ローレンス ジェイ．エヌ． クーパー
ドリュー シー． デニガー
ドリュー シー． デニガー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2016539929A publication Critical patent/JP2016539929A/ja
Publication of JP2016539929A5 publication Critical patent/JP2016539929A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
JP2016525990A 2013-10-25 2014-10-24 免疫療法のためのポリクローナルγδＴ細胞 Pending JP2016539929A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361895626P 2013-10-25 2013-10-25
US61/895,626 2013-10-25
PCT/US2014/062191 WO2015061694A2 (en) 2013-10-25 2014-10-24 Polyclonal gamma delta t cells for immunotherapy

Publications (2)

Publication Number Publication Date
JP2016539929A true JP2016539929A (ja) 2016-12-22
JP2016539929A5 JP2016539929A5 (enExample) 2017-11-30

Family

ID=52993756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016525990A Pending JP2016539929A (ja) 2013-10-25 2014-10-24 免疫療法のためのポリクローナルγδＴ細胞

Country Status (8)

Country Link
US (3) US9907820B2 (enExample)
EP (1) EP3060059A4 (enExample)
JP (1) JP2016539929A (enExample)
KR (1) KR20160068960A (enExample)
CN (1) CN105848484A (enExample)
AU (2) AU2014339926B2 (enExample)
CA (1) CA2926859A1 (enExample)
WO (1) WO2015061694A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022521027A (ja) * 2019-02-24 2022-04-04 ガミダ セル リミテッド 治療に使用する細胞組成物を生成するためのガンマ・デルタｔ細胞のホーミング及び保持の方法
JP2023544240A (ja) * 2020-08-12 2023-10-23 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド ガンマデルタｔ細胞を刺激するための方法及び組成物

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521406A (ja) 2004-11-24 2008-06-26 フレッド ハッチンソン キャンサー リサーチ センター 養子免疫療法のためのｉｌ−２１の使用法および腫瘍抗原の同定法
KR102238226B1 (ko) 2013-05-14 2021-04-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용
WO2014190273A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
KR102375998B1 (ko) 2014-02-14 2022-03-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 항원 수용체 및 제조방법
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
EP3215534B1 (en) 2014-11-05 2020-04-15 Board of Regents, The University of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
US11135245B2 (en) 2014-11-17 2021-10-05 Adicet Bio, Inc. Engineered γδ T-cells
US20220280564A1 (en) * 2014-11-21 2022-09-08 Immatics US, Inc. Methods for expanding t cells for the treatment of cancer and related malignancies
WO2016138091A2 (en) 2015-02-24 2016-09-01 Board Of Regents, The University Of Texas System Selection methods for genetically-modified t cells
CN107532174A (zh) 2015-03-11 2018-01-02 得克萨斯州大学系统董事会 转座酶多肽及其用途
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
CA3021226A1 (en) * 2015-05-11 2016-11-17 University Health Network Method for expansion of double negative regulatory t cells
WO2016183153A1 (en) * 2015-05-12 2016-11-17 Memorial Sloan Kettering Cancer Center Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy
PT3307875T (pt) * 2015-06-09 2022-03-21 Lymphact Lymphocyte Activation Tech S A Métodos para a produção de células t tcr gamma delta+
JP6799895B2 (ja) * 2015-06-09 2020-12-16 リンファクト−リンフォサイト アクティベイション テクノロジーズ エス．エー． ＴＣＲγδ＋Ｔ細胞の生産方法
KR20180041229A (ko) * 2015-08-25 2018-04-23 유에이비 리서치 파운데이션 줄기 세포 이식을 위한 방법
CN105112370B (zh) * 2015-08-25 2019-02-05 杭州优善生物科技有限公司 一种体外刺激外周血γδT细胞高效增殖的方法及其应用
KR20180042449A (ko) 2015-09-15 2018-04-25 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 T 세포 수용체(tcr) 결합 항체 및 이의 용도
CN105624107B (zh) * 2015-09-21 2020-06-12 杭州优善生物科技有限公司 一种多种淋巴细胞亚群的扩增方法及其应用
US11059879B2 (en) 2015-10-27 2021-07-13 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
AU2016344779B2 (en) 2015-10-30 2023-01-05 Cancer Research Technology Limited Expansion of non-haematopoietic tissue-resident gamma delta T cells and uses of these cells
JP7210286B2 (ja) * 2016-05-12 2023-01-23 アディセット バイオ， インコーポレイテッド γδＴ細胞集団の選択的増殖方法及びその組成物
TWI788307B (zh) * 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018081784A1 (en) * 2016-10-31 2018-05-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells for expanding immune cells for immunotherapy
WO2018147805A1 (en) * 2017-02-08 2018-08-16 Agency For Science, Technology And Research Gamma delta t cells and a method of augmenting the tumoricidal activity of the same
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
GB201707048D0 (en) * 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
CN109337872B (zh) * 2017-07-27 2023-06-23 上海细胞治疗研究院 高效扩增car-t细胞的人工抗原递呈细胞及其用途
US20200297871A1 (en) * 2017-09-15 2020-09-24 King's College London Compositions and methods for enhancing gamma delta t cells in the gut
CN107794269A (zh) * 2017-09-30 2018-03-13 成都美杰赛尔生物科技有限公司 促进基因编辑t细胞活化及扩增的生物膜、制法及应用
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
WO2019071358A1 (en) 2017-10-12 2019-04-18 Mcmaster University Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
IL274640B1 (en) 2017-11-15 2025-10-01 Adicet Bio Inc Methods for selective expansion of delta 3 gamma-delta T-cell populations and preparations thereof
CN108588023B (zh) * 2018-05-09 2020-02-14 河北森朗生物科技有限公司 一种生产嵌合抗原受体修饰的γδT细胞的方法
US10640562B2 (en) 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
BR112021005184A8 (pt) * 2018-09-19 2022-08-16 Lava Therapeutics B V Imunoglobulina cd1d de dupla ação
EP3856206A1 (en) * 2018-09-27 2021-08-04 Phosphogam, Inc. Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells
EA202190926A1 (ru) 2018-10-01 2021-06-25 Эдисет Био, Инк. Композиции и способы в отношении сконструированных и несконструированных t-клеток для лечения гематологических опухолей
KR20210087458A (ko) 2018-10-01 2021-07-12 아디셋 바이오, 인크. 고형 종양 치료를 위한 조작된 및 비-조작된 γδ-T 세포에 관한 조성물 및 방법
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
KR20220017892A (ko) * 2019-05-08 2022-02-14 얀센 바이오테크 인코포레이티드 T세포 매개 면역의 조절을 위한 물질 및 방법
WO2021016652A1 (en) * 2019-07-29 2021-02-04 The University Of Melbourne METHODS AND COMPOSITIONS FOR MONITORING, TREATING AND PREVENTING CMV INFECTION OR GRAFT REJECTION USING γδ T-CELLS
WO2021050789A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
CN111647070B (zh) * 2020-06-17 2022-06-03 深圳豪石生物科技有限公司 T细胞受体或其抗原结合片段及应用
KR20240037892A (ko) 2021-06-01 2024-03-22 트리움비라 이뮤놀로직스 유에스에이, 인크. 클라우딘 18.2 t 세포-항원 커플러 및 이의 용도
WO2023069322A1 (en) * 2021-10-20 2023-04-27 University Of Pittsburgh – Of The Commonwealth System Of Higher Education Methods and materials for expanding tumor infiltrating gamma-delta t cells
EP4433068A4 (en) * 2021-11-18 2025-11-12 Univ Minnesota LARGE-SCALE MULTIPLICATION OF MODIFIED HUMAN GAMMA T LYMPHOCYTES
EP4183871A1 (en) 2021-11-23 2023-05-24 Université d'Aix-Marseille Process for preparing a composition comprising a combined cell population
JP2025506506A (ja) 2022-02-16 2025-03-11 プリオセラ エスエーエス Ｓ１ｐ受容体モジュレーターと組み合わせたｃａｒ細胞を用いた処置方法
JP2025511408A (ja) * 2022-04-04 2025-04-15 ガンマデルタ セラピューティクス リミティッド 新規遺伝子アーマリング
CN114645022B (zh) * 2022-05-13 2022-09-02 首都医科大学宣武医院 靶向CD5的CAR-γ δ T细胞及其制备方法与应用
WO2025046256A1 (en) 2023-08-31 2025-03-06 Universite D'aix-Marseille Process for preparing a composition comprising a combined cell population
CN118064364B (zh) * 2024-04-19 2024-07-05 赛德特生物制药有限公司 一种γδT细胞的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535002A (ja) * 1999-01-28 2002-10-22 パルメット ヘルス アライアンス，デー／ビー／エー パルメット リッチランド メモリアル ホスピタル インビトロ活性化ガンマデルタリンパ球
JP2008500052A (ja) * 2004-05-27 2008-01-10 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規人工抗原提示細胞およびそれらの用途
WO2012156958A2 (en) * 2011-05-19 2012-11-22 Instituto De Medicina Molecular Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125884A0 (en) 1996-03-04 1999-04-11 Targeted Genetics Corp Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
JP5543207B2 (ja) * 2006-10-04 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不活性化された人工抗原提示細胞の調製および細胞治療におけるそれらの使用
EP2311470B1 (en) * 2008-07-01 2015-05-27 Medinet Co., Ltd. Method for simultaneous induction of ctl and gamma delta t cell
AU2009291595A1 (en) * 2008-09-11 2010-03-18 University Of Florida Research Foundation, Inc. System and method for producing T cells
US20120321666A1 (en) 2011-05-23 2012-12-20 Cooper Laurence J N T cell therapy for b cell lymphoma
WO2013074916A1 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535002A (ja) * 1999-01-28 2002-10-22 パルメット ヘルス アライアンス，デー／ビー／エー パルメット リッチランド メモリアル ホスピタル インビトロ活性化ガンマデルタリンパ球
JP2008500052A (ja) * 2004-05-27 2008-01-10 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規人工抗原提示細胞およびそれらの用途
WO2012156958A2 (en) * 2011-05-19 2012-11-22 Instituto De Medicina Molecular Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DENIGER，D. C.: "T-CELL TREATMENTS FOR SOLID AND HEMATOLOGICAL TUMORS", UT GSBS DISSERTATIONS AND THESES, JPN6019011015, August 2013 (2013-08-01), pages 89 - 161, ISSN: 0004158361 *
DENIGER: "T-CELL TREATMENTS FOR SOLID AND HEMATOLOGICAL TUMORS", UT GSBS DISSERTATIONS AND THESES, JPN5016011108, August 2013 (2013-08-01), pages 120 - 160, ISSN: 0004158359 *
EUR. J. IMMUNOL., vol. 39, JPN6019011014, 2009, pages 491 - 506, ISSN: 0004158364 *
J. TRANSL. MED., vol. 11, no. 37, JPN6018027871, February 2013 (2013-02-01), pages 1 - 10, ISSN: 0004158360 *
MOL. THER., vol. 21, no. 3, JPN6019011012, March 2013 (2013-03-01), pages 638 - 647, ISSN: 0004158362 *
PROTEIN CELL, vol. 2, no. 7, JPN6019011013, 2011, pages 585 - 599, ISSN: 0004158363 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022521027A (ja) * 2019-02-24 2022-04-04 ガミダ セル リミテッド 治療に使用する細胞組成物を生成するためのガンマ・デルタｔ細胞のホーミング及び保持の方法
JP2024088717A (ja) * 2019-02-24 2024-07-02 ガミダ セル リミテッド 治療に使用する細胞組成物を生成するためのガンマ・デルタｔ細胞のホーミング及び保持の方法
JP7546582B2 (ja) 2019-02-24 2024-09-06 ガミダ セル リミテッド 治療に使用する細胞組成物を生成するためのガンマ・デルタｔ細胞のホーミング及び保持の方法
JP2023544240A (ja) * 2020-08-12 2023-10-23 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド ガンマデルタｔ細胞を刺激するための方法及び組成物

Also Published As

Publication number Publication date
US9907820B2 (en) 2018-03-06
AU2014339926B2 (en) 2018-02-08
WO2015061694A3 (en) 2015-06-18
US20180200299A1 (en) 2018-07-19
EP3060059A4 (en) 2017-11-01
US20160256487A1 (en) 2016-09-08
CA2926859A1 (en) 2015-04-30
AU2014339926A1 (en) 2016-04-28
AU2018202976B2 (en) 2020-10-29
CN105848484A (zh) 2016-08-10
US20210187028A1 (en) 2021-06-24
AU2018202976A1 (en) 2018-05-31
WO2015061694A2 (en) 2015-04-30
EP3060059A2 (en) 2016-08-31
KR20160068960A (ko) 2016-06-15

Similar Documents

Publication Publication Date Title
US20210187028A1 (en) Polyclonal gamma delta t cells for immunotherapy
US20250034217A1 (en) Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
US11344577B2 (en) Car+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
KR102883631B1 (ko) 감마-델타 t 세포 및 자연 살해 세포의 치료 제제 및 제조 및 사용 방법
TWI875709B (zh) 製備表現嵌合抗原受體的細胞之方法
CN112204148B (zh) 具有增强功能的修饰的免疫细胞及其筛选方法
US11154572B2 (en) Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type
CA2938887C (en) Chimeric antigen receptors and methods of making
TW202134264A (zh) 嵌合抗原受體及其用途
TW201903145A (zh) 將基因編輯用於產生通用型ｔ細胞受體重導向的ｔ細胞以進行輸入免疫治療的用途
CN111247242A (zh) 嵌合抗原受体(CARs)、组合物及其使用方法
CN118355111A (zh) 同种异体人t细胞的可替代产生
US20210060070A1 (en) Adoptive cell therapy and methods of dosing thereof
US20220119476A1 (en) Activation of Antigen Presenting Cells and Methods for Using the Same
CN117858901A (zh) 制备表达嵌合抗原受体的细胞的方法
US20240060089A1 (en) Vector-free process for manufacture of engineered immune cells
TW202140790A (zh) 病毒載體轉導細胞的方法
JP2023543556A (ja) Ｃｄ２８膜貫通ドメインを有するキメラ抗原受容体（ｃａｒ）
WO2025214498A1 (en) Composition and method of cellular immunotherapy
TW202538050A (zh) 製備表現嵌合抗原受體的細胞之方法
HK40040871B (zh) 具有增强功能的修饰的免疫细胞及其筛选方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190822

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191121